Navigating Tariffs and Supply Chain Disruptions: Program Management Strategies for Pharmaceutical Commercial Success
Intense difficulties plague the pharmaceutical industry because of trade conflicts, implemented tariffs, and supply network disruptions that span multiple continents. The pharmaceutical sector encountered weaknesses due to political disputes and large-scale disruptions when the U.S.-China trade war started. The COVID-19 pandemic erupted, leading to cost hikes, medication delivery slowdowns, and an emptiness of essential medical resources emptiness. The situation worsens because API and essential material export duty barriers require immediate strategic solutions. Multiple complex industry challenges require companies to use program management as an essential success tool for achieving management success. Current program management requires developed methodologies to incorporate predictive risk assessment and improved capability to expand supply networks, manage regulatory compliance requirements, and implement flexible project methods for maintaining continuous profitable outcomes. The four strategic approaches companies must adopt are scenario planning integrated with multi-sourcing, predictive analytics, and tariff engineering to develop resilient supply chains in response to potential situations. Strategy implementation through integrated program management frameworks enables pharmaceutical firms to create risk-resistant organizations capable of seizing market possibilities without affecting external market changes. A strategic program management approach is an important weapon that helps businesses defeat supply chain instabilities and tariffs within their operations. According to the demands, pharmaceutical organizations must develop operational resilience factors for ongoing business success in volatile global markets. The research findings provide crucial intelligence to organizations with fragile global supply chain systems regarding becoming adaptable and developing innovative approaches for future planning.
Institutions
- Gilead Sciences (United Kingdom) (GB)
- Gilead Sciences (United States) (US)
- Gilead Sciences (Australia) (AU)
Publication Details
- Journal
- International Journal of Innovative Research in Science Engineering and Technology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.15680/ijirset.2025.1405010
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00